246 related articles for article (PubMed ID: 30965315)
1. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness.
Hesse E; Schröder S; Brandt D; Pamperin J; Saito H; Taipaleenmäki H
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30965315
[TBL] [Abstract][Full Text] [Related]
2. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.
Mendoza-Villanueva D; Zeef L; Shore P
Breast Cancer Res; 2011 Oct; 13(5):R106. PubMed ID: 22032690
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells.
Thouverey C; Apostolides P; Brun J; Caverzasio J; Ferrari S
JCI Insight; 2024 May; 9(10):. PubMed ID: 38713511
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
5. Excess TGF-β mediates muscle weakness associated with bone metastases in mice.
Waning DL; Mohammad KS; Reiken S; Xie W; Andersson DC; John S; Chiechi A; Wright LE; Umanskaya A; Niewolna M; Trivedi T; Charkhzarrin S; Khatiwada P; Wronska A; Haynes A; Benassi MS; Witzmann FA; Zhen G; Wang X; Cao X; Roodman GD; Marks AR; Guise TA
Nat Med; 2015 Nov; 21(11):1262-1271. PubMed ID: 26457758
[TBL] [Abstract][Full Text] [Related]
6. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.
Biswas S; Nyman JS; Alvarez J; Chakrabarti A; Ayres A; Sterling J; Edwards J; Rana T; Johnson R; Perrien DS; Lonning S; Shyr Y; Matrisian LM; Mundy GR
PLoS One; 2011; 6(11):e27090. PubMed ID: 22096521
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer bone metastases are attenuated in a Tgif1-deficient bone microenvironment.
Haider MT; Saito H; Zarrer J; Uzhunnumpuram K; Nagarajan S; Kari V; Horn-Glander M; Werner S; Hesse E; Taipaleenmäki H
Breast Cancer Res; 2020 Apr; 22(1):34. PubMed ID: 32272947
[TBL] [Abstract][Full Text] [Related]
8. Bone resorption and bone metastasis risk.
Mathis KM; Sturgeon KM; Winkels RM; Wiskemann J; De Souza MJ; Schmitz KH
Med Hypotheses; 2018 Sep; 118():36-41. PubMed ID: 30037612
[TBL] [Abstract][Full Text] [Related]
9. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.
Zhu M; Liu C; Li S; Zhang S; Yao Q; Song Q
Sci Rep; 2017 Sep; 7(1):11399. PubMed ID: 28900298
[TBL] [Abstract][Full Text] [Related]
11. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells.
Hiraga T; Horibe K; Koide M; Yamashita T; Kobayashi Y
Cancer Sci; 2023 Jun; 114(6):2460-2470. PubMed ID: 36840409
[TBL] [Abstract][Full Text] [Related]
13. MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption.
He Z; He J; Liu Z; Xu J; Yi SF; Liu H; Yang J
Biochimie; 2014 Nov; 106():24-32. PubMed ID: 25066918
[TBL] [Abstract][Full Text] [Related]
14. Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer.
Chen YC; Sosnoski DM; Gandhi UH; Novinger LJ; Prabhu KS; Mastro AM
Carcinogenesis; 2009 Nov; 30(11):1941-8. PubMed ID: 19759193
[TBL] [Abstract][Full Text] [Related]
15. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF.
Park BK; Zhang H; Zeng Q; Dai J; Keller ET; Giordano T; Gu K; Shah V; Pei L; Zarbo RJ; McCauley L; Shi S; Chen S; Wang CY
Nat Med; 2007 Jan; 13(1):62-9. PubMed ID: 17159986
[TBL] [Abstract][Full Text] [Related]
17. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway.
Zheng L; Gao J; Jin K; Chen Z; Yu W; Zhu K; Huang W; Liu F; Mei L; Lou C; He D
FASEB J; 2019 Jun; 33(6):7667-7683. PubMed ID: 30893559
[TBL] [Abstract][Full Text] [Related]
18. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.
Simone V; Ciavarella S; Brunetti O; Savonarola A; Cives M; Tucci M; Opinto G; Maiorano E; Silvestris F
BMC Cancer; 2015 Oct; 15():692. PubMed ID: 26468083
[TBL] [Abstract][Full Text] [Related]
19. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
Sun W; Shi Y; Lee WC; Lee SY; Long F
Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
